Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-0079-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD7 Monoclonal Antibody (eBio124-1D1 (124-1D1)), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The eBio124-1D1 monoclonal antibody reacts with human CD7, also known as gp40 and Leu9. CD7, a 40 kD receptor, is a member of the immunoglobulin gene superfamily. The N-terminal amino acid sequence (aa1-107) is highly homologous to Ig kappa light chain sequence; while the carboxyl-terminal region of the extracellular domain is proline-rich and has been postulated to form a stalk from which the Ig domain projects. CD7 is expressed on the majority of immature and mature T lymphocytes, and T cell leukemias. It is also found on natural killer cells, a small suppopulation of normal B cells and on maligant B cells. Cross-linking surface CD7 positively modulates T cell and NK cell activity, as measured by calcium flux, expression of adhesion molecules, cytokine secretion and proliferation. CD7 associates directly with phosphoinositol 3'-kinase. CD7 ligation induces production of D-3 phosphoinositides and tyrosine phosphorylation. A clonogenic subpopulation of human CD34(+) CD38(-) cord blood cells that express CD45RA and HLA-DR and high levels of the CD7 has been reported. These cells possess the capacity for lymphopoiesis. They can generate B-cells, natural killer cells, and dendritic cells but do not possess the capacity to develop into myeloid cells or erythroid cells. The CD7(+) phenotype distinguishes primitive human lymphoid progenitors from pluripotent stem cells. Furthermore, it has been suggested that CD7 co-operates with CD28 during Treg function, as mice deficient in both CD28 and CD7 have reduced total numbers of Tregs and these Tregs have reduced suppressive activity. Applications Reported: This eBio124-1D1 (124-1D1) antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBio124-1D1 (124-1D1) antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- eBio124-1D1 (124-1D1)
- Vial size
- 25 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references iPSC-Based Modeling of RAG2 Severe Combined Immunodeficiency Reveals Multiple T Cell Developmental Arrests.
Targeted Disruption of TCF12 Reveals HEB as Essential in Human Mesodermal Specification and Hematopoiesis.
High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells.
Adipocyte-derived soluble factor(s) inhibits early stages of B lymphopoiesis.
Generation of bivalent chromatin domains during cell fate decisions.
Identification of CD7 as a cognate of the human K12 (SECTM1) protein.
Identification of CD7 glycoprotein as an accessory molecule in HIV-1-mediated syncytium formation and cellfree infection.
Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system.
Themeli M, Chhatta A, Boersma H, Prins HJ, Cordes M, de Wilt E, Farahani AS, Vandekerckhove B, van der Burg M, Hoeben RC, Staal FJT, Mikkers HMM
Stem cell reports 2020 Feb 11;14(2):300-311
Stem cell reports 2020 Feb 11;14(2):300-311
Targeted Disruption of TCF12 Reveals HEB as Essential in Human Mesodermal Specification and Hematopoiesis.
Li Y, Brauer PM, Singh J, Xhiku S, Yoganathan K, Zúñiga-Pflücker JC, Anderson MK
Stem cell reports 2017 Sep 12;9(3):779-795
Stem cell reports 2017 Sep 12;9(3):779-795
High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells.
Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T
Molecular & cellular proteomics : MCP 2016 Apr;15(4):1246-61
Molecular & cellular proteomics : MCP 2016 Apr;15(4):1246-61
Adipocyte-derived soluble factor(s) inhibits early stages of B lymphopoiesis.
Bilwani FA, Knight KL
Journal of immunology (Baltimore, Md. : 1950) 2012 Nov 1;189(9):4379-86
Journal of immunology (Baltimore, Md. : 1950) 2012 Nov 1;189(9):4379-86
Generation of bivalent chromatin domains during cell fate decisions.
De Gobbi M, Garrick D, Lynch M, Vernimmen D, Hughes JR, Goardon N, Luc S, Lower KM, Sloane-Stanley JA, Pina C, Soneji S, Renella R, Enver T, Taylor S, Jacobsen SE, Vyas P, Gibbons RJ, Higgs DR
Epigenetics & chromatin 2011 Jun 6;4(1):9
Epigenetics & chromatin 2011 Jun 6;4(1):9
Identification of CD7 as a cognate of the human K12 (SECTM1) protein.
Lyman SD, Escobar S, Rousseau AM, Armstrong A, Fanslow WC
The Journal of biological chemistry 2000 Feb 4;275(5):3431-7
The Journal of biological chemistry 2000 Feb 4;275(5):3431-7
Identification of CD7 glycoprotein as an accessory molecule in HIV-1-mediated syncytium formation and cellfree infection.
Sato AI, Balamuth FB, Ugen KE, Williams WV, Weiner DB
Journal of immunology (Baltimore, Md. : 1950) 1994 May 15;152(10):5142-52
Journal of immunology (Baltimore, Md. : 1950) 1994 May 15;152(10):5142-52
Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system.
Aruffo A, Seed B
The EMBO journal 1987 Nov;6(11):3313-6
The EMBO journal 1987 Nov;6(11):3313-6
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of normal human peripheral blood cells with 0.5 µg of Mouse IgG1 K Isotype Control Purified (Product # 14-4714-82) (open histogram) or 0.5 µg of Anti-human CD7 Purified (filled histogram) followed by F (ab')2 Anti-Mouse IgG PE (Product # 12-4010-82). Cells in the lymphocyte gate were used for analysis.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 An Increase in CD7 - CD56 + CD33 + NK Cell-like Cells in RAG2SCID iPSC Differentiation Cultures (A and B) (A) Plotted percentages of iPSC-derived CD7 + CD56 + NK cells and (B) CD7 - CD56 + cells. (C) Flow cytometric analysis of CD33 and CD14 (myeloid) and CD16 and NKG2D (NK cell) expression in the CD7 - CD56 + population. (D) Production of cytokines by CD7 - CD56 + and CD7 + CD56 + cells measured after 20 h of stimulation with IL-12, IL-15, and IL-18. Results are from at least three independent experiments. Averages + standard deviations are shown. ** p < 0.01.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7 HEBCan Rescues Hematopoiesis and T Cell Development in HEB -/- hESCs in OP9-DL4 Co-cultures (A) qRT-PCR analysis for the expression of hematopoietic genes in CD34 + cells sorted from WT, KO + GFP, and KO + HEBCan day-8 (d8) EBs. mRNA levels are shown relative to GAPDH. (B and C) Percentages (B) and numbers (C) of CD45 + cells in d12 and d18 OP9-DL4 co-cultures. (D and E) Flow-cytometric analysis of T cell development from WT, KO + GFP, and KO + HEBCan d8 EB-derived CD34 + cells at d12 (D) and d18 (E) of OP9-DL4 co-culture. Cells are gated on the CD45 + DAPI - population. Error bars represent mean +- SD (n = 3 independent experiments). * p < 0.05, ** p < 0.01, *** p < 0.005 by Student's t test. Plots in (B), (D), and (E) are representative of three independent experiments.